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Abstract
Background: Late-onset Pompe disease (LOPD) is a rare treatable lysosomal storage disorder characterized by
progressive lysosomal glycogen accumulation and muscle weakness, with often a limb-girdle pattern. Despite
published guidelines, testing for LOPD is often overlooked or delayed in adults, owing to its low frequency
compared to other muscle disorders with similar muscle patterns. Next-generation sequencing has the capability to
test concurrently for several muscle disorders. This could potentially lead to increased diagnosis of LOPD, disorders
with non-specific muscle weakness or atypical patients.
Methods: We developed a gene panel to further study its clinical utility in a cohort of patients with suspected
muscle disorders. We designed a gene panel to analyze the coding sequences and splice site junctions of GAA
causing LOPD, along with 77 other genes causing muscle disorders with overlapping phenotypes.
Results: At a median coverage of ~200X (sequences per base), all GAA exons were successfully covered with >20X
and only 0.3 % of exons across all genes were <20X. The panel showed an excellent sensitivity (100 %) and
specificity (98 %) across all selected genes, using known variations in Pompe patients and controls. We determined
its clinical utility by analyzing 34 patients with suspected muscle disorders of undetermined etiology and various
muscle patterns, who were referred or followed in neuromuscular and genetics clinics. A putative diagnosis was
found in up to 32 % of patients. The gene panel was instrumental in reaching a diagnosis in atypical patients,
including one LOPD case. Acid alpha-glucosidase activity was used to confirm the molecular results in all patients.
Conclusion: This work highlights the high clinical utility of gene panels in patients with suspected muscle disorders
and its potential to facilitate the diagnosis of patients showing non-specific muscle weakness or atypical
phenotypes. We propose that gene panels should be used as a first-tier test in patients with suspected muscle
disorders of undetermined etiology, which could further increase overall diagnosis of muscle conditions, and
potentially reduce diagnostic delay. Further studies are necessary to determine the impact of first-tier gene panels
on diagnostic delay and on treatment outcome for LOPD.
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Background
Pompe disease (OMIM 232300) is an autosomal reces-
sive condition caused by mutation in the GAA gene,
leading to a deficiency in acid alpha-glucosidase (OMIM
606800, EC 3.2.1.20) and accumulation of glycogen in all
tissues, most notably in muscles and heart [1, 2]. Pompe
disease consists of a phenotypic continuum, however
two broad categories are recognised: classic infantile and
late onset forms [3, 4]. Classical infantile Pompe disease
presents in the first few months of life with hypertrophic
cardiomyopathy, generalized muscle weakness, and re-
spiratory distress [5]. Without enzyme replacement ther-
apy (ERT), the disease is fatal within the first year of life
in the vast majority of infantile cases [6]. Late-onset
Pompe disease (LOPD) may present at any age from late
infancy onwards, but most frequently develops during
adulthood, either with motor delays or limb-girdle
muscle weakness [7]. Some patients present with rigid
spine syndrome, scoliosis and low body mass [7]. Dia-
phragmatic weakness is present in the vast majority of
patients and leads to nocturnal hypoventilation. Pre-
symptomatic patients can be identified by persistent,
chronic elevation of serum creatine kinase, and a recent
study showed a frequency of Pompe disease in 2.5% of
patients with chronic hyperCKemia [8]. The combined
incidence of all forms of Pompe disease at birth is esti-
mated to be 1:40,000 in the US and similarly in
Netherlands, with the adult onset form being 1:57,000
[9, 10]. However, recent data from newborn screening
program of Missouri state, Austria and Taiwan suggest
that incidence is higher with respectively 1:5463, 1:8684
and 1:11,987 [11–13]. LOPD is likely underdiagnosed in
neuromuscular clinics owing to the rarity of the condi-
tion and its marked phenotypic variability.
Since early diagnosis, followed with prompt initiation
of ERT, may significantly improve its clinical benefits,
universal screening has been advocated as a way to im-
prove outcomes in Pompe patients [14]. For LOPD, de-
layed diagnosis is not unusual and has been reported to
be made almost 10 years after the onset of symptoms
[15]. Pilot newborn screening programs are in develop-
ment or in progress in the US, and are well established
in Taiwan using dried blood spots [16–18]. Although
LOPD cases can be detected by newborn screening, un-
diagnosed children and adults will not benefit from on-
going development of these screening programs. Current
methodologies to confirm the diagnosis of Pompe
include mutation analysis by Sanger sequencing and en-
zyme testing in fibroblasts or leukocytes using fluorimet-
ric methods, or more recently, on dried blood spot by
tandem mass spectrometry [4, 19, 20]. All these methods
are contingent on a strong clinical suspicion of Pompe
disease and do not detect the presence of other muscle
disorders. Given the rarity of Pompe disease and despite
published diagnostic guidelines to educate clinicians,
testing for Pompe disease is often overlooked [4]. The
need exists for more comprehensive diagnostic tools tar-
geting Pompe disease among other muscle disorders
with overlapping clinical manifestations. The differential
diagnosis of Pompe disease includes many genetic
muscle disorders with limb-girdle weakness or rigid
spine syndrome, which may be difficult to differentiate
on a clinical basis alone [4]. However, next-generation
sequencing (NGS) has the capability to test concurrently
for all these muscle disorders.
NGS technologies make it possible to perform several
millions of accurate sequence reactions in parallel on
solid support, each producing a short sequence called a
“read” [21]. Sequence enrichment methods are available
to limit the analysis to the exons of selected genes of
interest (gene panels). Pitfalls of sequence enrichment
include low number of sequence reads in GC-rich re-
gions or very low GC content, which would need to be
sequenced by the conventional Sanger method to pre-
vent false negatives [22, 23].
We developed a gene panel to simultaneously analyze
genes associated with several muscle disorders with
overlapping phenotypes in order to increase the diagno-
sis of LOPD in children and adults, of other disorders
with non-specific muscle patterns and of patients with
atypical presentations. We validated this gene panel
using CEPH cell line NA12878 and samples from known
Pompe patients and determined its clinical validity
among a group of patients with undetermined muscle
disorders. In parallel, we validated a method to deter-
mine acid alpha-glucosidase activity on dried blood spots
(DBS) by tandem mass spectrometry, and correlated the
enzyme activity data with results from the gene panel.
Methods
Gene panel design
We included genetic disorders that are part of the differ-
ential diagnosis of LOPD [4, 24]: muscular dystrophies
with limb-girdle weakness pattern, rigid spine syn-
dromes, scapuloperoneal syndromes, congenital myas-
thenic syndromes, congenital myopathies (nemaline,
myofibrillar), congenital muscular dystrophies, metabolic
myopathies (fatty acid oxidation disorders, glycogen
storage disorders), and peroxisomal disorders. We ex-
cluded disorders for which the main molecular defect
could not be detected reliably by NGS (repeat expan-
sions and structural variants), such as fascioscapulohum-
eral dystrophy. Mitochondrial genes (mtDNA and
nuclear) were excluded as well, owing to the large num-
ber of genes involved. The gene list was circulated
among collaborators with special expertise in Pompe
disease, medical and biochemical genetics, and neuroge-
netics. The final gene panel comprised 78 genes
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(Additional file 1: Table A). In order to design oligo-
nucleotide probes for sequence enrichment, we delin-
eated the genomic coordinates of exons of selected
genes (all alternate transcripts) based on GRCh37/hg19
genome assembly and RefSeq gene definition (11/2013).
Genomic coordinates were sent to Nimblegen Bioinfor-
matics Production team (Madison, USA) to complete
the design of the oligonucleotide probes, based on the
exome enrichment kit V3. We allowed up to five perfect
matches on the human genome for each probe to
maximize the number of selected genomic regions cov-
ered, when necessary. In-solution hybridization oligo-
nucleotide probe library was produced accordingly to
SeqCapEZ® technology (Roche/Nimblegen)
Determination of the analytical validity of the gene panel
We analysed 20 Pompe patients and the NA12878
CEPH cell line to determine the sensitivity and specifi-
city of the gene panel. The genome of NA12878 has
been analyzed by multiple sequencing platforms and
high quality confident genotypes are available to assess
sensitivity and specificity (http://genomeinabottle.org)
[25]. DNA was obtained from known Pompe patients,
followed at the Division of Medical Genetics at Duke
University Medical Center. All patients have been diag-
nosed on the basis of decreased acid alpha-glucosidase
enzyme activity and had results from GAA Sanger se-
quencing available. Known mutations and polymor-
phisms were used for comparison with results from
NGS (Additional file 1: Table B).
Next-generation sequencing
Sequencing of the gene panel by NGS was performed as
follows: DNA from samples was fragmented to a mean
size of ~350bp by sonication (Covaris M220). Then, se-
quencing libraries were prepared with TruSeq® library kit
(Illumina) according to the manufacturer’s protocol, ex-
cept for the following modifications at the library ampli-
fication step by LM-PCR: in order to minimize
amplification bias related to GC content, we substituted
the provided polymerase by the KAPA HIFI HotStart
polymerase (KAPA biosystems), and we used the follow-
ing amplification conditions with initial denaturation for
45 sec at 98 °C, followed by seven cycles with 15 sec at
98 °C, 30 sec at 60 °C and 30 sec at 72 °C, ending with
final extension step 1 min at 72 °C. We then performed
enrichment of exonic and flanking intronic sequences of
selected genes in 12 samples in a multiplex reaction
using our custom in-solution hybridization oligonucleo-
tide probe library (SeqCapEZ®, Nimblegen). We followed
the manufacturer’s protocol, but decreased the number
of post-capture amplification cycles to 13 to minimize
amplification bias related to GC content. Enrichment ef-
ficiency was measured by quantitative PCR for one GC-
rich locus (GAA exon 14, 66 % GC content) and 2 loci
with average GC-content (TPM1 exon 1, 57 % GC;
MYBPC3 exon 6, 53 % GC). Multiplexed samples were
sequenced if they met a minimal acceptable enrichment
factor of 800-1000X. Sequencing was done on a MiSeq®
sequencer (Illumina) using paired-end protocol (150 pb)
and V2 chemistry. On average, 12.4 millions of pass fil-
ter reads were produced per sequencing run with 95.4%
of reads having an average Phred score quality above
Q30 (1 error in 1000 bases).
Bioinformatics analysis
We analyzed the sequencing data on a Linux-based bio-
informatics pipeline developed by MUGQIC (https://bit-
bucket.org/mugqic/mugqic_pipelines). Briefly, 1) raw
reads were trimmed using Trimmomatic (version 0.32)
[26], 2) sequence alignment was performed with
Burrows-Wheeler Aligner (version 0.7.10) [27], 3) gen-
etic variations (SNP and indels) were called with haplo-
typeCaller using the Genome Analysis Toolkit (version
3.2.2) [28, 29] with prior local realignment, base recali-
bration and removal of PCR duplicates using Picard
(version 1.123, http://broadinstitute.github.io/picard/), 4)
gene annotation was performed with SnpEff/SnpSift
(version 3.6, including SIFT, Polyphen2, MutationTaster
predictions) [30] with an additional in-house script to
annotate variations present in ClinVar database [31], 5)
a filtering process removed variations outside targeted
sequences, with population frequency >1 % (dbSNP 138
and ExAC 0.3; http://exac.broadinstitute.org), genotype
quality less than Q30 or present in 3/20 or more local
controls sequenced on the same platform (therefore con-
sidered as artefacts). In order to identify single exon de-
letions in the GAA gene, we manually inspected the read
coverage depth across GAA for each patient compared
to NA12878 cell line, using the Integrative Genomics
Viewer (see Additional file 1: Figure A) [32]. Small dele-
tions (less than 3 exons), remain challenging for current
software [33–35]. Coverage depth was calculated using
Browser Extensible Data (BED) Tools [36] and SAM-
tools [37] from the Galaxy web-based platform [38], as
described in detail in the Additional file 1.
Measurement of the acid alpha-glucosidase enzyme
activity in dried blood spots (DBS) by tandem mass
spectrometry
The method for the acid alpha-glucosidase activity mea-
surements in DBS was adapted from Dajnoki et al. [39]
and is described in detail in the Additional file 1. The en-
zyme activity was analyzed in 3.2 mm diameter DBS discs.
The acid alpha-glucosidase substrate ([7-benzoylamino-
heptyl)-{2-[4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydr
o-pyran-2-yloxy)-phenylcarbamoyl]-ethyl}-carbamic acid t
ert-butyl ester] and its internal standard (IS) [7-d5-
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benzoylamino-heptyl)-[2-(4-hydroxyphenylcarbamoyl)-
ethyl]-carbamic acid tertbutyl ester] were manufactured
by Genzyme, A Sanofi Division (Framingham, MA) and
distributed by the Centers for Disease Control and Pre-
vention (CDC), Newborn Screening Branch, (Atlanta,
GA). The product of the enzymatic reaction and its
internal standard were analyzed by tandem mass spec-
trometry using a Quattro Micro (Waters Corp.) in the
multiple reaction monitoring mode in positive electro-
spray ionization.
Assessment of clinical utility of the gene panel
We recruited pediatric and adult patients with undeter-
mined muscle disorders referred to or already followed
at specialized neuromuscular or genetic clinics in differ-
ent provinces in Canada (Sherbrooke, Saguenay,
Montreal in Quebec and Calgary, Alberta). Inclusion
and exclusion criteria are shown in Fig. 1. Each partici-
pant provided written informed consent. The study was
approved by the institutional ethics committee of the
Université de Sherbrooke (project 12-208). A blood sam-
ple was drawn from each participant for DNA extraction
(QIAamp DNA blood mini kit, Qiagen) and a DBS spe-
cimen was collected to measure acid alpha-glucosidase
enzyme activity. For 24 patients, whole blood was col-
lected in sodium heparinized tubes and enzyme testing
was performed on leucocytes by previously described
standard spectrophotometric assay [40].
NGS followed by bioinformatic analysis was then per-
formed on the DNA sample as described above. Cover-
age depth of exons of GAA in all patients was manually
reviewed for heterozygous exon deletions as described in
2.4, owing to the relatively high frequency of whole exon
18 deletion. Similarly, in patients with a single causal
variation in recessive disorders, we searched the relevant
gene for heterozygous exon deletion. Suspected hetero-
zygous exon deletions were confirmed by qPCR analysis
or Sanger sequencing if breakpoints were known. In pa-
tients who did not have causal variations identified, 6
exons with consistently insufficient coverage (<20X;
SGCB exon 1, SEPN1 exon 1 and 3, PLEC exon 32,
FKRP part of exon 4, PEX10 exon 1) were sequenced to
exclude mutations by the Sanger method on a 3730XL
DNA analyzer (Applied Biosystems) at McGill University
and Genome Quebec Innovation Center. Putative causal
variations were sequenced in parents when available and
were classified accordingly to the ACMG recommenda-
tions [41].
Results
The gene panel comprises GAA along with 77 other
genes causing muscle disorders that are considered in
the differential diagnosis of LOPD [4, 24]. The complete
gene list is available in the Additional file 1 section
(Table A). Before investigating the clinical utility of the
gene panel, we sought to determine the analytical valid-
ity of our method across all targeted genes and more
specifically for GAA, the gene responsible for Pompe
disease. We sequenced the NA12878 CEPH cell line in
two independent sequencing runs, among known Pompe
patients and neuromuscular patients for a total of 12
samples per sequencing run.
Analytical validity of the gene panel
We determined the sensitivity and specificity across all
selected genes by performing a comparison of observed
genotypes with reference genotypes of the CEPH cell
line NA12878. The genome of NA12878 has been ana-
lyzed by multiple sequencing platforms and high quality
reliable genotypes are available to assess sensitivity and
specificity (http://genomeinabottle.org) [25]. We ob-
served a sensitivity of 100 % (95 % C.I.: 99–100 %) using
a set of 373 known variations (359 SNV and 14 indels)
across all selected genes. Median coverage was 216X and
only 6/1720 exons (0.3 %) did not show a coverage
depth consistently above 20X, which would need Sanger
sequencing to exclude variations. All GAA exons were
successfully covered with >20X. In order to calculate the
specificity, we restricted our analysis to variations lo-
cated in exons and splice site junctions (+/- 5 bp), which
Inclusion criteria
There is no age restriction. Criteria 1, 2 and 3 must be met:
1. Clinical presentation characterised by (a OR b):
a. At least one of the following motor symptoms:
i. Motor delay in a child, as per Denver developmental scale
ii. Generalized hypotonia in a child as per physical examination 
by a physician
iii. Muscle weakness (any pattern), as per physical examination by
a physician
iv. Muscle atrophy, (any pattern), as per physical examination by a
physician
v. Respiratory distress due to muscle involvement (i.e. diaphragm 
or accessory respiratory muscles) requiring recurrent or 
permanent assistance  
vi. Rigid spine syndrome
b. Chronic and unexplained creatine kinase blood level without 
significant muscle weakness, as defined by at least two creatine kinase 
blood levels that are twice the upper limit of normal , spaced at least 
one month apart. 
2. At least one of the following laboratory investigations showing results
suggestive of muscle involvement:
a. Electromyogram and nerves conductive studies
b. Creatine kinase blood level 
c. Muscle biopsy (not diagnostic of a specific disease)
d. Muscle MRI
3. Unconfirmed underlying disorder when refered to the neuromuscular or 
genetic clinic. Negative deletion/duplication analysis for Duchenne / 
Becker muscular dystrophy if clinically indicated. 
Exclusion criteria








Fig. 1 Inclusion and exclusion criteria
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are more relevant for disease causing variations. Deep
intronic regions contain more frequently repetitive se-
quences that yield higher false positive rates. A total of
208 variations (204 SNV and 4 indels) were detected in
exons and splice site junctions of selected genes. Among
these, four variations (1 indel) were not found in the
reference genotypes, which yielded a specificity of 98 %
(95 % C.I.: 95–99 %).
We analysed the sequencing data of 20 Pompe patients
with known mutations and polymorphisms to determine
more specifically the sensitivity of our method for varia-
tions located in the GAA gene. Our gene panel showed a
100 % sensitivity (95 % C.I.: 98–100 %) based on the
analysis of 197 known single nucleotide variations and
indels (36 SNV and 6 indels; Additional file 1: Table B).
Median coverage of GAA for each Pompe patient se-
quenced ranged from 72X to 150X. All GAA exons were
successfully covered with >20X. In addition, deletion of
whole exon 18 was correctly detected by manual read
depth inspection in 5/5 Pompe patients.
Validation of DBS acid alpha-glucosidase activity by
tandem mass spectrometry
For the tandem mass spectrometry method validation,
quality control (QC) DBS at four different enzyme levels
of activity (from low QC1 to high QC4) were supplied
by the CDC and used to measure the intra- and interday
assay precision of the method (Table 1). Fifteen DBS
from diagnosed Pompe patients were analyzed as posi-
tive quality controls and 49 DBS from healthy controls
were analyzed to establish normal values for the GAA
enzyme activity. The GAA activity was abnormal, with
mean 0.51 (observed range nd-3.09) μmol/h/L for the 15
diagnosed Pompe patients and normal, with mean 8.57
(observed range 4.72–16.36) μmol/h/L for the 49 healthy
controls. These results show that our method, which is
scaled down from the current large-scale protocol [39]
and is thus less expansive, provides a similar high quality
of results.
Clinical utility of the gene panel
We assessed the clinical utility of the gene panel in a co-
hort of pediatric and adult patients referred and followed
at specialized neuromuscular and genetic clinics for an
undetermined suspected muscle disease. A total of seven
pediatric and 27 adult patients were recruited and se-
quenced. Median coverage for each patient ranged from
81X to 361X, for a mean of 168X. Most patients pre-
sented with proximal muscle weakness or a more diffuse
pattern with distal involvement (Table 2). At the time of
recruitment 24/34 patients (71 %) had undergone a
muscle biopsy and 15/34 (44 %) had at least one single
gene test performed, but remained without a diagnosis.
We identified one Pompe patient harbouring 2 known
pathogenic variations (P29), the c.-32-13T > G mutation,
associated with LOPD, and the recurrent exon 18 dele-
tion. In four other patients, we identified pathogenic var-
iations supportive of an inherited muscle disorder
(Table 3), for a diagnostic yield of 15 %. Likely patho-
genic variations, variants of uncertain clinical signifi-
cance or a combination of both were found in six
patients, suggesting additional diagnoses. In three of
these patients, revision of available muscle biopsy or
additional immunohistochemistry supported the diagno-
sis (P22, P25, P27). In the three others, family history
was in agreement with expected heritability, but samples
were not available for segregation study. In total, a puta-
tive diagnosis was found in 11/34 (32 %) patients
(Table 3). Most diagnoses showed various types of limb-
girdle muscular dystrophies, although some had atypical
presentations with respect to the causative gene (P25,
P28, P29; see section 3.4). Acid alpha-glucosidase en-
zyme activity yielded normal results in all but one pa-
tient (P29), while abnormally low enzyme activity for
P29 supported the diagnosis of Pompe disease made by
molecular analysis (Table 3). One DBS sample was
rejected on the basis of low control enzymes in addition
to acid alpha-glucosidase, likely secondary to insufficient
biological material (patient P27). Enzyme testing could
not be repeated on a second sample, but a putative
causal variation in the VCP gene was found. Delay from
initial symptoms to diagnosis ranged from 1 year in
pediatric patients to more than 20 years in adults. In pa-
tients without diagnosis, we observed 0–5 heterozygous
variants of uncertain significance altering the protein se-
quence of different recessive disorders.
Atypical cases
Patient P25 showed unusual late onset of symptoms for
a patient with NEB mutations. The patient had normal
birth history and psychomotor development. Objective
Table 1 GAA enzyme activity intra- and interday assays using
DBS from low to high quality controls (QCs)
Intraday assays (n = 5)
QC1 QC2 QC3 QC4
Mean (μmol/h/L) 0.28 0.84 6.79 13.67
Range (μmol/h/L) 0.20–0.49 0.75–0.89 6.20–7.64 11.50–15.83
RSD% 41.42 6.44 8.70 12.79
Interday assays (n = 5)
QC1 QC2 QC3 QC4
Mean (μmol/h/L) 0.33 1.00 7.29 13.70
Range (μmol/h/L) (0.17–0.53) (0.69–1.44) (6.85–7.69) (12.08–15.09)
RSD% 38.75 27.17 4.22 9.37
RSD relative standard deviation
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diffuse mild muscle weakness was only documented in
adulthood. However, muscle weakness might have pre-
ceded adulthood since reduced body weight was re-
ported in early teenage years with decreased tolerance
for moderate intensity exercise. However, no further in-
vestigation was performed at that time, until adulthood.
Muscle biopsy showed nemaline inclusions in a config-
uration supporting a diagnosis of CAP myopathy. Se-
quencing of TPM2, TPM3 and ACTA1 was negative. The
patient remains fully ambulatory. Patient 28 showed an
unusual severe and early onset of symptoms for a het-
erozygous carrier of a truncating mutation in DMD. She
presented with limb girdle weakness before 10 years of
age, high CK and limited long distance walking. There
was no family history of affected males with muscular
dystrophy, and she had a daughter who showed similar
symptoms at 11 years. Muscle biopsy performed in the
context of autosomal dominant limb-girdle dystrophy
failed to support a specific diagnosis. Patient P29, who
was diagnosed with Pompe disease, showed a peculiar
phenotype, which likely contributed to delay in diagno-
sis. The patient is a female born prematurely at 32 weeks
of gestational age. She showed motor and language
delay, with walking at 3 years and first words around 2.5
years. Neuropsychological evaluation revealed a mild in-
tellectual deficit. She received a diagnosis of cerebral
palsy early in the course. She was otherwise known for
obesity, hypertension and past history of seizures. Al-
though she was reported to present long lasting gait dis-
turbances, it was only at the age of 36 years that
Table 2 Recruited patients with undermined muscle disease
Clinical presentation Nbr of patients (pediatric patients) Proportion of clinical presentations (%) Proportion of diagnoses (%)
Motor delay or generalized hypotonia 4 (4) 4/34 (11.8%) 2/11 (18%)
Limb-girdle muscle weakness 17 (1) 17/34 (50.0%) 6/11 (55%)
Proximal and distal limb muscle weakness 4 (2) 4/34 (11.8%) 3/11 (27%)
Other muscle weakness 3 (0) 3/34 (8.8%) 0/11 (0%)
Chronic and unexplained hyperCKemia 6 (0) 6/34 (17.6%) 0/11 (0%)
Total 34 (7) 100% 11/34 (32%)










P11 10 6 Proximal and distal limb
muscle weakness
COL6A1 c.1059 + 1 G > Aa
(Pathogenic)
- Bethlem myopathy (AD)
P13 11 0.3 Motor delay DNAJB6 c.525C > G p.Phe175Leu
(VUS)
- LGMD1E (AD)
P17 21 11 Proximal and distal limb
muscle weakness





P20 35 25 Limb-girdle muscle
weakness





P21 56 N/A Limb-girdle muscle
weakness
COL6A3 c.5658G > A p.Arg1886Cys
(VUS)
- Bethlem myopathy (AD)
P22 46 <26 Limb-girdle muscle
weakness










c.24113C > A p.Ser8038Ter
(Likely path.)
Nemaline myopathy (AR)
P27 60 57 Limb-girdle muscle
weakness
VCP c.1158T > C p.Lys386Glu
(VUS)
- Inclusion body myopathy
(AD)
P28 43 <10 Limb-girdle muscle
weakness (female)




P29 48 <36 Limb-girdle muscle
weakness
GAA c.-32-13T > G (Pathogenic) Exon 18 deletion
(Pathogenic)
Pompe disease (AR)
P30 1 0 Motor delay and
generalized hypotonia
POMT2 c.1997A > Gb p.Tyr666Cys
(Pathogenic)




ade novo variation; bParental heterozygous carrier status confirmed; N/A Not available, VUS variant of uncertain significance. Variations were classified accordingly
to the ACMG recommendations
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progression of the disease made her unable to climb
stairs at home and she began to use a walker. Weakness
progressed and she became wheelchair-bound at the age
of 47 years. At 48 years old, respiratory insufficiency was
noted and treated with non-invasive ventilation at night.
A muscle biopsy was performed and showed glycogen
accumulation, and the patient was referred to the genet-
ics clinic for suspicion of Pompe disease. Diagnosis was
established on the basis of the acid alpha-glucosidase ac-
tivity and mutation analysis as described above. In short,
the delay from initial symptoms to diagnosis was at least
12 years and possibly more, owing to the long lasting
history of gait disturbances. Enzyme replacement ther-
apy was initiated in the weeks following the diagnosis
and response is currently being assessed.
Discussion
Our work highlights the high clinical utility of gene
panels in patients with suspected muscle disorders and
their potential to facilitate the diagnosis of patients
showing non-specific muscle weakness or atypical phe-
notypes. This gene panel approach might further in-
crease diagnosis of muscle conditions and reduce
diagnostic delay. We propose that gene panels should be
used as a first-tier test in patients with suspected muscle
disorders of undetermined etiology. With decreasing se-
quencing costs and increasing availability of NGS-based
tests, there are several advantages of performing gene
panels early in the investigation of patients with muscle
weakness.
Firstly, gene panels offer a higher clinical utility than
any single disorder test by enabling screening for several
diseases with overlapping phenotypes at the same time.
This is especially useful in the context of patients with
non-specific muscle patterns, such as children with
motor delay or adults with limb-girdle patterns which
are frequently encountered in neuromuscular and genet-
ics clinics. There are more than 25 different types of
limb-girdle muscular dystrophies, which often could not
be distinguished clinically [42]. Moreover, muscle biopsy
and immunostains are of very limited utility to target
molecular tests in some instances, such as ANO5 (pa-
tient P25) [42]. In these latter cases, diagnosis could re-
quire several molecular single gene tests which can be
prohibitive when considering the broader differential
diagnosis of limb-girdle muscle weakness: Pompe dis-
ease, dystrophinopathies, Bethlem myopathy, myofibril-
lar myopathies, metabolic myopathies and others [42].
All these conditions would be readily diagnosed with a
gene panel like the one we have developed. In the
present study, the rate of diagnosis reached up to 32 %
of patients tested, with 50 % presenting with limb-girdle
weakness. Since our cohort is enriched for patients who
have been followed for years in specialized clinics
without diagnosis and 44 % of patients had previous
negative molecular tests results, one would expect a
higher rate of diagnosis if the gene panel was performed
as a first-tier test. Previous studies performing targeted
next generation sequencing, similarly as a second tier
test in patients with muscular dystrophies, reported
diagnostic yields ranging from 16 to 65 % [43–45]. Even
if no treatment is available for the majority of these con-
ditions, benefits of genetic diagnosis include more accur-
ate prognostic information, genetic counselling, family
screening and prenatal diagnosis in severe cases.
Secondly, use of gene panels in patients with muscle
weakness could facilitate the diagnosis of atypical pheno-
types, and reduce diagnostic delay. Delay in diagnosis
varied from 1 year in pediatric patients to more than 20
years in adults included in the present study. Patients
P25, P28, and P29 showed atypical or unusual character-
istics that likely contributed to delayed diagnosis. P25
showed unusual late onset of symptoms for NEB muta-
tions and biopsy showed features supporting a diagnosis
of CAP myopathy. Most cases of NEB mutations present
in the neonatal period or within the first years of life, al-
though some late-onset presentations have been de-
scribed [46–48]. Moreover, mutations in NEB was not a
known cause of CAP myopathy at the time of clinical
evaluation and had only been reported recently in a sin-
gle case [49]. Patient P28, harbouring a truncating muta-
tion in DMD, presented unusual severe limb-girdle
weakness of pediatric onset. In the two largest reported
series of DMD mutation carriers, the proportion of man-
ifesting carriers varied from 5 to 22 % and the pediatric
cases remained rare [50, 51]. However, in recent studies,
female carriers with pediatric onset of muscle weakness
are becoming increasingly recognized [52, 53]. In our
case, absence of affected male and a similarly affected
daughter on family history further contributed to confu-
sion about inheritance, leading to an erroneous working
diagnosis of autosomal limb girdle dystrophy. Finally,
the peculiar disease course and spectrum of clinical
manifestations of P29, possibly related in part to prema-
ture birth and complications, certainly contributed to
delay in the recognition of Pompe disease by at least 12
years. This is not unusual as final diagnosis was reported
to be made almost 10 years after the onset of symptoms
in LOPD [15]. Although this is debatable, earlier accessi-
bility to our gene panel at the age of 36 years while pro-
gression to limb-girdle weakness became significant
could have led to a more rapid diagnosis for this patient,
and possibly a different outcome at 48 years of age.
While we agree that Pompe disease should be consid-
ered in all patients with limb-girdle weakness, in practice
it is likely that screening through acid alpha-glucosidase
activity will not necessarily be requested by every adult
neurologist owing in part to the low frequency of LOPD.
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In our view, gene panels represent a more comprehen-
sive first-tier diagnostic option in this type of scenario,
and are more likely to be adopted by the medical com-
munity. Nevertheless, it remains to be determined
whether broad adoption of gene panel as a first-tier test
would result in significant reduced delay in the diagnosis
of LOPD leading to an impact on treatment outcome.
This question is timely as next generation sequencing
becomes more widespread in al practice clinic and also
considering the current populations of children and
adult who will not benefit from ongoing implementation
of newborn screening.
The pitfalls of using gene panels as first-tier analysis in
the place of enzyme activity for identification of Pompe
disease include the identification of variants of unknown
significance (VUS), detection of a single heterozygous
mutation, and limited performance of current bioinfor-
matic tools to detect deletions and duplications from
targeted NGS data [33–35, 41]. The VUS rates will
greatly vary from gene to gene, but large collaborative
efforts to share mutation data, such as ClinVar, are un-
derway to minimise this limitation [31]. In Pompe dis-
ease, 19 % of 84 GAA variants reported in ClinVar that
were not classified as likely benign, are of uncertain clin-
ical significance (June 2015). The Pompe disease muta-
tion database (www.pompecenter.nl/, June 2015) lists 71
variations with unknown effect among 426 variations (17
%) that are not classified as likely benign [54]. Conse-
quently, most patients present with two pathogenic al-
leles, but enzyme testing may be needed as reflex testing
in those harbouring a VUS [55–58]. In the present study,
we did not identify VUSs in GAA in our cohort of 34 pa-
tients, although we observed 0–5 VUS per patient across
all genes analyzed. Pompe patients with a single hetero-
zygous mutation identified are uncommon and represent
2–17 % of patients with enzyme-based diagnosis from
several case series [55–58]. Assessment of recurrent
exon 18 deletion and other deletions in the GAA gene is
critical to minimize this number. Currently, bioinfor-
matic identification of deletions and duplications with
targeted NGS-based data is of limited sensitivity, espe-
cially for less than three exons [33–35]. However, we
managed to detect the recurrent exon 18 deletion from
manual inspection of read coverage compared to a con-
trol. As for VUSs, reflex enzyme testing is necessary here
to exclude that a GAA mutation was missed. Owing to
these limitations, testing for acid alpha-glucosidase activ-
ity would appear the test of choice in the context of a
strong clinical suspicion of Pompe disease.
The current state of NGS technology favors the use of
gene panels over exome sequencing in the clinical set-
ting, although this is likely to change in upcoming years.
Beside the higher cost of exome sequencing, the main
disadvantage is related to more incomplete coverage of
exonic sequences (~5 %) owing to generally lower aver-
age coverage compared to panels [59–61]. Raising the
average coverage of exome sequencing to reach those of
gene panels will only lead to further increase of its cost
disadvantage. In addition, it has to be demonstrated that
the diagnostic yield of exome sequencing is significantly
superior to a well-designed clinical panel [59, 60]. Vari-
ants detected in genes that are ambiguously or not yet
related to the patient’s phenotype are likely to be of lim-
ited clinical utility. Interestingly, a recent study using ex-
ome sequencing showed similar yield compare to our
study with 22 of 74 patients (30 %) classified as muscular
dystrophies and related disorders [62]. Another study,
from the Emory Genetics Laboratory, reported that ex-
ome sequencing missed about 18 % of causative patho-
genic variants detected by their neuromuscular gene
panel [60]. Obviously, exome sequencing raises add-
itional issues including increased number of VUSs, inci-
dental findings and higher laboratory infrastructure cost
for clinical implementation.
Conclusion
Our work highlights the high clinical utility of gene
panels in patients with muscle disorders and its potential
to facilitate the diagnosis of patients showing non-
specific muscle weakness or atypical phenotypes. This
could potentially lead to earlier diagnosis, if performed
as a first-tier test. It remains to be determined if this
would have a significant impact on treatment outcome
for LOPD.
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